Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
| Autor: | Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, Di Bona G, Lee S, Henriksen JH, Ruiz del Arbol L, Angeli P, Garcia Tsao G, Gülberg V, Guevara M, Moreau R, Ortega R, Kamath P, Moore K, Mullen K, Sanyal A, Blendis L, Terg R., BERNARDI, MAURO |
|---|---|
| Přispěvatelé: | Universitat de Barcelona, Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, Di Bona G, Lee S, Henriksen JH, Ruiz del Arbol L, Angeli P, Garcia-Tsao G, Gülberg V, Guevara M, Moreau R, Ortega R, Kamath P, Moore K, Mullen K, Sanyal A, Bernardi M, Blendis L, Terg R. |
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cirrosi hepàtica Hepatorenal Syndrome Cirrhosis LIVER CIRRHOSIS medicine.medical_treatment education MEDLINE Lypressin Therapeutics Liver transplantation DIAGNOSIS Malalties dels ronyons Liver disease Medicina preventiva Diagnòstic Hepatorenal syndrome Renal Dialysis Albumins Diagnosis Ascites Humans Vasoconstrictor Agents Medicine Infusions Parenteral Intensive care medicine Preventive medicine Kidney diseases business.industry TREATMENT General Medicine Terapèutica medicine.disease PREVENTION Liver Transplantation Surgery Transplantation Hepatic cirrhosis Portasystemic Shunt Transjugular Intrahepatic medicine.symptom Refractory ascites business Terlipressin |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona Recercat. Dipósit de la Recerca de Catalunya instname |
| ISSN: | 1469-0756 0032-5473 |
| DOI: | 10.1136/gut.2006.107789 |
| Popis: | Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its functional nature, HRS is associated with a poor prognosis,3 4 and the only effective treatment is liver transplantation. During the 56th Meeting of the American Association for the Study of Liver Diseases, the International Ascites Club held a Focused Study Group (FSG) on HRS for the purpose of reporting the results of an international workshop and to reach a consensus on a new definition, criteria for diagnosis and recommendations on HRS treatment. A similar workshop was held in Chicago in 1994 in which standardised nomenclature and diagnostic criteria for refractory ascites and HRS were established.5 The introduction of innovative treatments and improvements in our understanding of the pathogenesis of HRS during the previous decade led to an increasing need to undertake a new consensus meeting. This paper reports the scientific rationale behind the new definitions and recommendations. The international workshop included four issues debated by four panels of experts (see Acknowledgements). The issues were: (1) evidence-based HRS pathogenesis; (2) treatment of HRS using vasoconstrictors; (3) other HRS treatments using transjugular intrahepatic portosystemic stent-shunt (TIPS) and extracorporeal albumin dialysis (ECAD); and (4) new definitions and diagnostic criteria for HRS and recommendations for its treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|